Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00547469Phase 2Unknown

A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females

Role: lead

NCT00230581Phase 2Completed

8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

Role: lead

NCT00252993Phase 2Terminated

12 Weeks Treatment With DDP225 or Placebo in Patients With Chronic Functional Vomiting

Role: lead

NCT00215566Phase 2Completed

A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c

Role: lead

All 4 trials loaded